| Address: | 4796 Executive Dr, San Diego, CA 92121, USA |
|---|---|
| Postal code: | 92121 |
| Phone: | (800) 826-6411 |
| Website: | https://otiprio.com/contact-us/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Otiprio, use the form below and your opinion, advice or comment will appear in this space.
CONTRAINDICATIONS. OTIPRIO (ciprofloxacin otic suspension) 6% is contraindicated in patients with a history of hypersensitivity to ciprofloxacin To report suspected adverse events, product complaints, or request product information, please contact our Customer Service Center at 1-800-826-6411.
Otonomy announced that the Food and Drug Administration (FDA) has approved Otiprio (ciprofloxacin otic suspension) for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube For more information call (800) 826-6411 or visit Otiprio.com.
http://otonomy.com. Drugs. OTIPRIO.
http://otonomy.com. Drugs. OTIPRIO.
See full prescribing information for OTIPRIO. OTIPRIO® (ciprofloxacin otic suspension), for intratympanic or otic use Initial U.S. Approval To report SUSPECTED ADVERSE REACTIONS, contact Otonomy at 1-800-826-6411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
http://otonomy.com. Drugs. OTIPRIO.
Compare Otiprio prices, print discount coupons, find Otiprio (ciprofloxacin otic) is a member of the otic anti-infectives drug class and is commonly used for Acute Otitis Externa and Tympanostomy Tube Placement Surgery. More information please phone: 844-684-7746 or 800-826-6411 Visit Website.
(2.1) • OTIPRIO is intended for single-patient use with two 0.1. mL doses available in each vial. (2.1) • Administer OTIPRIO as a single intratympanic. To report SUSPECTED ADVERSE REACTIONS, contact Otonomy at 1-800-826-6411 or FDA at 1-800-FDA-1088 or www fda.gov/medwatch.
Otonomy at 1-800-826-6411 or FDA at 1-800-FDA-1088 or … observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies … OSE RCM #: 2015-2141-1. DMEPA Primary Reviewer: … Human Factor Study Result and Label and Labeling Review for Otiprio …
OTIPRIO is indicated for The treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Otonomy at 1-800-826-6411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.